Literature DB >> 22004042

Long-term efficacy of plasma exchange treatment for refractory Kawasaki disease.

Tatsunori Hokosaki1, Masaaki Mori, Takashi Nishizawa, Tomoko Nakamura, Tomoyuki Imagawa, Mari Iwamoto, Shumpei Yokota.   

Abstract

BACKGROUND: The treatment of Kawasaki disease patients who fail to respond to initial i.v. immunoglobulin (IVIG) therapy is controversial. The aim of the present study was to investigate the long-term efficacy of plasma exchange (PE) treatment for refractory Kawasaki disease.
METHODS: A total of 125 Kawasaki disease patients refractory to IVIG were treated with PE. Coronary artery lesions (CAL) before PE, in the acute period, and during the late period were examined retrospectively.
RESULTS: Residual sequelae requiring medical treatment occurred in six cases in the late period. The outcomes of treatment tended to be better when PE was begun in the early stage. Sequelae remained in 2.8% of patients in whom PE was initiated prior to day 9 after onset, and were present in 15% of patients in whom PE was started on or after day 10. The 105 patients whose coronary arteries were normal before PE had no sequelae (residual sequelae: 0%). Dilatation was present before PE in 14 patients, but remained in only two patients in the late period (residual sequelae, 14.3%). In four of the six patients in whom aneurysms had already formed before PE, the lesions had advanced into giant aneurysms, but in the other two patients they returned to the normal range (residual sequelae, 66.6%).
CONCLUSIONS: The outcomes of PE for Kawasaki disease refractory to IVIG are favorable, and the effectiveness of this treatment is excellent, particularly if it is initiated before CAL arise.
© 2011 The Authors. Pediatrics International © 2011 Japan Pediatric Society.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22004042     DOI: 10.1111/j.1442-200X.2011.03487.x

Source DB:  PubMed          Journal:  Pediatr Int        ISSN: 1328-8067            Impact factor:   1.524


  22 in total

Review 1.  Kawasaki disease: insights into pathogenesis and approaches to treatment.

Authors:  Stanford T Shulman; Anne H Rowley
Journal:  Nat Rev Rheumatol       Date:  2015-04-28       Impact factor: 20.543

Review 2.  2021 Update on the Clinical Management and Diagnosis of Kawasaki Disease.

Authors:  Frank Zhu; Jocelyn Y Ang
Journal:  Curr Infect Dis Rep       Date:  2021-02-06       Impact factor: 3.725

Review 3.  Treatment Options for Resistant Kawasaki Disease.

Authors:  Linny Kimly Phuong; Nigel Curtis; Peter Gowdie; Jonathan Akikusa; David Burgner
Journal:  Paediatr Drugs       Date:  2018-02       Impact factor: 3.022

4.  Effect and Safety of TNF Inhibitors in Immunoglobulin-Resistant Kawasaki Disease: a Meta-analysis.

Authors:  Li-Jun Xue; Rong Wu; Gui-Lian Du; Yan Xu; Kang-Yan Yuan; Zhi-Chun Feng; Yu-Lin Pan; Guang-Yu Hu
Journal:  Clin Rev Allergy Immunol       Date:  2017-06       Impact factor: 8.667

Review 5.  Corticosteroids for the treatment of Kawasaki disease in children.

Authors:  Jessica Green; Andrew J Wardle; Robert Mr Tulloh
Journal:  Cochrane Database Syst Rev       Date:  2022-05-27

Review 6.  Corticosteroids for the treatment of Kawasaki disease in children.

Authors:  Andrew J Wardle; Georgia M Connolly; Matthew J Seager; Robert Mr Tulloh
Journal:  Cochrane Database Syst Rev       Date:  2017-01-27

Review 7.  Is dosing of therapeutic immunoglobulins optimal? A review of a three-decade long debate in europe.

Authors:  Jacqueline Kerr; Isabella Quinti; Martha Eibl; Helen Chapel; Peter J Späth; W A Carrock Sewell; Abdulgabar Salama; Ivo N van Schaik; Taco W Kuijpers; Hans-Hartmut Peter
Journal:  Front Immunol       Date:  2014-12-12       Impact factor: 7.561

8.  Resolution of Giant Coronary Aneurisms in a Child With Refractory Kawasaki Disease Treated With Anakinra.

Authors:  Alessandro Gambacorta; Danilo Buonsenso; Gabriella De Rosa; Ilaria Lazzareschi; Antonio Gatto; Federica Brancato; Davide Pata; Piero Valentini
Journal:  Front Pediatr       Date:  2020-05-07       Impact factor: 3.418

Review 9.  Kawasaki disease: pathophysiology, clinical manifestations, and management.

Authors:  Victoria R Dimitriades; Amanda G Brown; Abraham Gedalia
Journal:  Curr Rheumatol Rep       Date:  2014-06       Impact factor: 4.686

10.  Safety and efficacy of plasma exchange therapy for Kawasaki disease in children in intensive care unit: case series.

Authors:  Satoko Noguchi; Junichi Saito; Tomoyuki Kudo; Eiji Hashiba; Kazuyoshi Hirota
Journal:  JA Clin Rep       Date:  2018-03-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.